Replimune’s Post

#DidYouKnow – there are hundreds of clinical trials that melanoma patients can join. You may be able to join a clinical trial before or after you’ve tried other FDA-approved treatments & you will get the standard of care that is the usual FDA-approved treatment for your melanoma subtype. We invite you to review this clinical trial infographic, developed in partnership with Bristol Myers Squibb, to learn more about clinical trials - https://buff.ly/43MfoFT

Reminder to come by Plus Therapeutics at the SNMMI 2024 Annual Meeting in Toronto at Booth #1948 Learn about the latest ReSPECT-LM Clinical Trial data for Leptomeningeal Metastases and view our newest poster in the poster hall Two accepted abstracts titled: 1) "Rhenium (186Re) obisbemeda (186RNL) in leptomeningeal metastases (LM) Phase 1/2A Dose Escalation Trial: Update of Initial Safety and Feasibility through Cohorts 1-4" 2) "Radiation Absorbed Dose to Spinal Cord: Therapy of Leptomeningeal Metastasis Using Beta-Emission Radiopharmaceuticals" Posters will be available on https://lnkd.in/eQXB5zz5 after the conference. #SNMMI #BrainCancer #Glioblastoma #BreastCancer #LungCancer #Melanoma #ClinicalTrials 

Did you miss our webinar on 'The Ongoing Expansion of Subcutaneous Anti-Cancer Therapies (SACT) supported by Roche? The full webinar is now available on our YouTube channel. 📺 Watch it here: https://lnkd.in/guVxfBR2

A new first-line treatment for #CLDN18.2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma patients could be #FDA approved! In clinical trials, zolbetuximab, a first-in-class CLDN18.2-directed antibody, significantly prolonged progression-free survival when added to standard-of-care chemotherapy. Discover the details of this trial in our latest edition⭐: https://bit.ly/4aIciFV

Join us today at the Presidential symposium at #WCLC24 to hear Dr. Patrick Forde discuss the patient-level data analysis for EFS outcomes in patients with resectable non-small cell #lungcancer from the CheckMate-77T and CheckMate-816 trials. This is the first individual patient-level data analysis of two randomized Phase 3 trials assessing which patients may derive benefit from adjuvant immunotherapy in perioperative #immunotherapy-based regimens. #LCSM https://bit.ly/3MH60vb

For patients, drug development timelines are not fast enough. At Viracta, we are actively working to accelerate our clinical trial timelines to meet the needs of patients living with EBV-associated cancer today. #TeamViracta will be carrying this early 2024 energy throughout the year.  Read more about our clinical trial updates and outlook for 2024 here 👇 https://lnkd.in/gdCzUdxc #news #EBV #lymphoma #clinicaltrials

Innovation continues to transform modern care for patients with #MultipleMyeloma (MM). New developments with CD38 antibodies and BCMA immunotherapy have clear implications for oncology nurses, who play a pivotal role in the management of MM as caregivers, educators, patient advocates, and conduits for the coordination and delivery of care. In collaboration with the HealthTree Foundation for Multiple Myeloma and #ONS2024, this #PeerView Seminar and Nurse Workshop initiative will feature a panel of expert oncology nurses who will use a series of ten case-based learning sessions to provide guidance on modern patient assessment, therapy selection, dosing, and adverse event management when using CD38 antibody platforms, BCMA immunotherapies, and other innovative therapeutics. Register today and don’t miss this opportunity to join the #oncology #nurse experts Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO, Donna Catamero, ANP-BC, OCN, CCRC, and Charise Gleason NP, MSN, NP-C, AOCN, to take steps to improve patient care! https://bit.ly/MM24L #MedEd #ONS2024 This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi

Capivasertib approved to treat patients with advanced breast cancer The active substance capivasertib is part of a group of medicines called AKT inhibitors. It blocks the effects of proteins called ATK Kinases, which enable cancer cell growth and multiplication. By blocking their action, capivasertib can reduce the growth and spread of the advanced breast cancer and help to destroy cancer cells. https://lnkd.in/dCKtSMWF

We are advancing a broad pipeline across a number of high-value therapeutic areas, and we are working to execute on our milestones associated with it. Listen to our CEO discuss what you can expect to see next here: https://bit.ly/3Xguylq #PancreaticCancer #OvarianCancer #BreastCancer #ColorectalCancer #LongCOVID #MECFS

Olaparib is authorised as "maintenance" treatment (with or without bevacizumab) in women with certain ovarian cancers following first-line chemotherapy. In both authorised clinical situations, the initial authorisation was based on a single double-blind randomised clinical trial, with an interim analysis showing no reduction in mortality after a median follow-up of about 40 months. As of mid-2023, longer-term results are available from both of these trials ➡ https://lnkd.in/eHDz-JRy